TrialBritish journal of haematology2023

Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results.

Johnny Mahlangu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.